I nfantile hemangiomas (IHs) are the most common benign tumors of infancy, affecting approximately 5% of children. 1 These vascular tumors present 2 to 3 weeks after birth and proliferate for approximately 1 year. The clinical appearance of IH can be highly variable and range from a small, superficial lesion to a large, deep tumor. 2 Beginning at 10 to 12 months and lasting up to 10 years, most IHs involute and resolve without intervention. The lesions that result from atrophy of IHs can form permanent residual changes including scarring and fibro-fatty residuum. 3 The current hypothesis for cellular origin of IH is the hemangioma stem cell (HemSC). Hemangioma stem cells have a high proliferation rate, can differentiate into multiple cell types, and can form functional, GLUT1+ hemangioma endothelial cell (HemEC)Ylined blood vessels in matrigel-implanted animal models. 4 Although IHs are benign, these tumors can become problematic for infants, causing visual or airway impairment, disfigurement, or ulceration. 2 The use of propranolol has been added to the treatment armamentarium of longstanding conventional therapies including corticosteroids and surgery for high-risk IHs. 5, 6 Since its serendipitous discovery in 2008 as an effective treatment for severe IH, 7 propranolol has been used worldwide and for various types of compromising hemangiomas, even replacing corticosteroids as a first-line therapy in many cases. 8Y11 Despite the widespread use of this effective therapy, its mechanism of action in IH is not yet understood.
Studies have shown that propranolol increases vasoconstriction while also decreasing proliferation rates of HemECs in vitro. 4,10,12Y15 Recently, we have shown that propranolol also affects HemSCs, causing accelerated adipogenesis. In the absence of adipogenic induction, propranolol increased proadipogenic gene expression in HemSCs as early as 24 hours after starting treatment. 4 Our results showed that propranolol had a proadipogenic effect in HemSCs, in addition to its ''anti-angiogenic'' effects in IH. 16 In this study, we further demonstrate that during adipogenic induction, propranolol promotes dysregulated adipogenesis, by improper regulation of proadipogenic genes, followed by eventual cell death. This may in part explain propranolol's influence in initiating early tumor involution, as well as its overall effectiveness as a therapeutic for IH.
METHODS

Cell Isolation
Institutional review board approval for collection of resected human hemangiomas was obtained from Columbia University College of Physicians and Surgeons (IRB #AAAA9976). Written informed consent was obtained for all tissue obtained. Tissues were used immediately for cell isolation for in vitro experiments. Hemangioma stem cells were isolated from clinically resected specimens using the Miltenyi BIotec (Auburn, Calif ) magnetic cell sorting system selecting for CD133+ cells. 4, 17 Hemangioma stem cell identity was confirmed by successful differentiation into adipocytes, endothelial cells, and osteocytes in vitro and recapitulation of IH histology in vivo in a nude mouse model. 17 
Tissue Culture and Treatment With Propranolol
Hemangioma stem cells were maintained on fibronectin-coated, 10-cm plates in EGM-2 and 20% fetal bovine serum. Medium was changed every other day, and cells at passage numbers 10 to 20 were used for all experiments.
Propranolol hydrochloride (Sigma, St Louis, Mo) was reconstituted at 100 KM in pH 3.0 dH 2 O (hereafter referred to as ''vehicle''). For experimentation, fresh propranolol was added to culture media during media changes at indicated concentrations.
RNA Isolation and Complementary DNA Generation
Total RNA was isolated with the RNeasy Mini Prep Kit (Qiagen, Germantown, Md). Complementary DNA was synthesized by reverse transcription of 2 Kg of total RNA, performed using the Superscript II Reverse Transcriptase Kit (Invitrogen, Grand Island, NY).
Quantitative Real-Time Polymerase Chain Reaction
Real-time quantitative polymerase chain reaction was performed in triplicate using the CFX Real-Time PCR Detection System (Bio-Rad, Hercules, Calif ) and ABsolute Blue QPCR SYBR Green Mix (Applied Biosystems, Foster City, Calif ). The results were normalized to A-actin expression levels and samples were analyzed in triplicates. Gene expression levels for C/EBP>, C/EBPA, and C/EBPC, PPARC, PPARF, RXR>, and RXRF were determined (Table 1) .
Adipogenic Differentiation
Adipogenic differentiation was performed as previously described. 4 Brief ly, 10 4 HemSC were seeded on fibronectin-coated, 8-well Nunc Lab-Tek II chamber slides (Thermo Fisher Scientific, Waltham, Mass) in EGM-2/20% FBS. On the following day, cells were washed once with phosphate-buffered saline and then cultured in adipogenic media [Dulbecco modified Eagle medium low glucose (Invitrogen), 10% fetal bovine serum, 1% penicillin/streptomycin (Invitrogen), 5 Kg/mL of insulin (Sigma), 1 KM dexamethasone (Sigma), 0.5 mM isobutylmethylxanthine (Sigma), and 60 KM indomethacin (Sigma)] for 4 days in the presence of 50 or 100 KM propranolol or vehicle. Adipogenic differentiation was assessed by Oil Red O staining for lipid droplets after 4 days of treatment in adipogenic media.
Annexin V Measurement by Fluorescence-Activated Cell Sorting
Hemangioma stem cells were grown to 75% conf luence in EGM-2/FBS 20%. Cells were then exposed to vehicle, 10, or 100 KM propranolol for 24 hours. Levels of annexin V and propidium iodide (PI) expression by HemSCs were measured using the Annexin V-FITC Apoptosis Detection Kit (BioVision, Milpitas, Calif ) according to the manufacturer's instructions. Differentiation between apoptosis and necrosis was made by comparing levels of annexin V and PI, respectively. The FACSCalibur flow cytometer (BD Biosciences, San Jose, Calif ) was used for antibody detection.
RESULTS
Propranolol Induced Cell Death in HemSCs During Adipogenesis
Hemangioma stem cells were grown in adipogenic medium with either propranolol (50 or 100 KM) or vehicle for 4 days (Fig. 1 ). Differences in cell density were observed after 24 hours in the propranololtreated cells in a dose-dependent manner. Vehicle-treated HemSCs were 90% to 95% confluent, whereas HemSCs in 100 KM propranolol were 40% to 50% confluent and had begun to detach. By day 4, vehicle-treated cells were still 90% to 95% confluent. In contrast, HemSCs treated with 50-KM propranolol were less confluent (80%Y85%) and beginning to detach, whereas cells treated with 100-KM propranolol were less than 10% confluent, and displayed an altered cell morphology.
Adipogenesis was also determined by Oil Red O staining. Hemangioma stem cells treated with 50-KM propranolol had an increase in lipid droplet formation relative to vehicle-treated cells (Fig. 2) , consistent with increased adipogenic differentiation. Thus, we found that propranolol increased the rate of adipocyte differentiation and promoted HemSC detachment characteristic of increased cell death.
Cell Death in Propranolol-Treated HemSCs Was not Caused by Apoptosis
Next, we wanted to determine the mechanism of cell death after 2 days in adipogenic media. Cell death was assessed by the Annexin V Apoptosis Detection Kit and PI uptake. Consistent with the increased HemSC cell detachment, PI uptake was increased in propranolol-treated HemSCs in a dose-dependent manner (Fig. 3) . However, levels of annexin V remained unchanged for each treatment type. Taken together, these data suggest that propranolol induced cell death by an apoptosis-independent mechanism.
Propranolol Induced Dysregulated Adipogenesis in HemSCs
We hypothesize that the cell death observed in response to propranolol may be due to defective or incomplete adipocyte differentiation. To assess this, we evaluated the expression of adipogenic genes at day 1 and day 4 posttreatment with 50-KM propranolol relative to day 0 before adipogenic induction. The gene expression levels were determined for the CCAAT/enhancer-binding proteins C/EBP>, C/EBPA, and C/EBPC (transcription factors commonly up-regulated during adipogenesis), peroxisome proliferator-activated receptors PPARC, PPARF (receptors well established for modulating adipocyte differentiation), and retinoid X receptors, RXR> and RXRF (nuclear receptors known to heterodimerize with PPAR proteins). We found 3 distinct gene expression patterns ( Fig. 4) . At days 1 and 4, transcript levels of C/EBPA, C/EBPC, and PPARF were significantly increased above vehicle-treated cells (3.4, 3.3, and 2.8fold, respectively, at day 1), consistent with the observation of early fat vacuole formation (P G 0.01). In vehicle-treated cells, PPARC levels decreased at days 1 and 4 relative to day 0. In contrast, PPARC was significantly up-regulated in the propranolol-treated HemSCs at days 1 and 4 relative to day 0. Propranolol-treated HemSCs showed a significant decrease in RXR>, and RXRF transcript levels when compared to vehicle (1.6 and 3.2-fold, respectively, by day 1; P G 0.05). Finally, C/EBP>, a gene required for terminal differentiation, had an attenuated induction in propranolol-treated cells (48-fold at day 4) when compared to vehicle (840-fold increase at day 4) (P G 0.005) ( Fig. 4) .
DISCUSSION
Since 2008, propranolol has been known to be an effective empirical treatment for problematic IHs. There are multiple studies on the antiangiogenic effects of propranolol on endothelial cells (including HemECs). 16, 18 We have shown that propranolol also has other effects, including changing HemSCs proliferation and differentiation into adipocytes. 4 Here, we further demonstrate that the propranolol induced dysregulated adipogenesis associated with increased cell death and improper induction of proadipogenic genes. As fibrofatty tissue is typically found in involuting or involuted IH, our results suggest that propranolol acts on both the endothelium and the fatty residuum associate with IHs.
Although accelerated adipogenesis was observed as early as 24 hours after propranolol treatment, treated HemSCs also showed decreased cellular confluence over the time course of the experiment, indicating a departure from the typical mitotic clonal expansion normally found in early adipogenesis of committed preadipocytes. 19, 20 Our results suggest that there was increased cell death in propranolol-treated HemSCs, and this was confirmed with increased PI expression. Our analysis of annexin V expression showed that levels remained unchanged during treatment, suggesting that mechanisms of cell death other than apoptosis may be involved. Léauté-Labrèze et al 7 postulated that propranolol-induced IH cell death may be due to apoptosis of endothelial cells. Our study concentrated on propranolol's effects in HemSCs, and our findings suggest that propranolol induces necrosis versus apoptosis in these cells. Future experiments on HemECs will help clarify the role of apoptosis in propranolol-induced IH involution. Furthermore, we will study other possible triggers of cell death that are distinct from apoptosis, such as anoikis (a mechanism of cell death induced by detachment) or paraptosis (a caspase-independent mechanism characteristic of extensive cytoplasmic vacuolization). 21 The dysregulation in adipogenesis seen in propranolol-treated HemSCs was confirmed by the changes in gene expression profile during adipogenesis. We have previously shown that propranolol increased transcripts in multiple proadipogenic genes in basal media even in the absence of adipogenic stimulation. The only exception was C/EBP>, which was not changed. 4 This study shows the adipogenic gene expression was perturbed during early adipogenesis. Proadipogenic genes such as C/EBPA and C/EBPC are known to be increased early in the differentiation process, 22Y24 and these were all up-regulated in propranolol-treated HemSCs as compared to vehicle-treated HemSCs. Elevated expression levels of PPARF were seen at the 24-hour mark, a gene that is usually expressed later in adipogenesis during terminal differentiation. 20, 25 Although PPARF was increased in the propranolol treatment group at both time points, the difference was more dramatic at day 1, supporting the early acceleration seen in propranolol-treated cells. This could explain the increase in lipid formation observed in the 50-KM propranolol-treated HemSC.
Other genes required for differentiation, including RXR> and RXRF, were found to be down-regulated in propranolol-treated 20, 22 As treatment with propranolol seems to significantly down-regulate the expression of RXR factors, it can be inferred that differentiation is at least partially hindered through the limitation of PPAR-RXR heterodimer formation. Thus, the increase in PPAR levels may not result in increased signaling as RXRs are decreased.
Perhaps the most drastic departure from normal physiological transcription levels during treatment is that of C/EBP>, an integral factor that oversees terminal adipogenesis alongside PPARF. 23, 24 Under physiological conditions, C/EBP> is induced by C/EBPA and C/EBPC, and its expression is associated with terminal adipocyte differentiation. Although propranolol treatment increased expression of C/EBPA and C/EBPC, they failed to induce C/EBP> expression. In knockdown models, white adipose tissue fails to develop in C/EBP> j/j mice. 26, 27 The loss of C/EBP> induction therefore may explain the failure in adipocyte differentiation and subsequent cell death observed in propranolol-treated HemSCs.
Understanding the observed departure in gene expression profile of normal adipocyte development may help understand the mechanism by which propranolol acts on IHs. Our studies have shown upregulation of genes that cause accelerated early adipogenesis. In addition, we have shown that propranolol down-regulated genes that are necessary for completion of differentiation. However, further study is 
